Table 1 Basic information on the 5 clinical trials included in this meta-analysis
Study | Sample size (n) | Design | Duration | Dose mg/kg/day | Procedure |
|---|---|---|---|---|---|
Study 1 (S) Svanborg et al, 2009 [36] | 99 | Randomized, double-blind, placebo-controlled | 10 weeks | 1.2 | Diagnosis based on ADHD-RS, confirmed with KSADS, stimulant-naïve patients No ongoing psychotropic medication or structured PT |
Study 2 (E) Escobar et al, 2009 [37] | 149 | Randomized, double-blind, placebo-controlled | 12 weeks | 1.2 | Diagnosis based on ADHD-RS, confirmed with KSADS stimulant-naïve patients No ongoing psychotropic medication or structured PT CGI≥4 at inclusion |
Study 3 (I) Dell'Agnello et al, 2007 [38] | 139 | Randomized, double-blind, placebo-controlled | 8 weeks | 1.2 | Diagnosis based on ADHD-RS, confirmed with KSADS, ADHD+ODD patients No ongoing psychotropic medication or structured PT CGI≥4 at inclusion |
Study 4 (UK) Prasad et al, 2007 [23] | 201 | Open-label, atomoxetine vs standard of care | 10 weeks | 0.5-1.8 | Diagnosis based on ADHD-RS, confirmed with KSADS No ongoing psychotropic medication or structured PT |
Study 5 (CAN) Dickson et al, 2007 [39] | 206 | Open-label, atomoxetine only | 12 weeks | 0.5-1.4 | Diagnosis based on ADHD-RS, confirmed with KSADS |